Pharmacological investigation of the mechanisms of platelet-activating factor induced mortality in the mouse.
Although the platelets of the mouse are refractory to the direct effects of platelet-activating-factor (PAF), tail vein injection of 10-150 micrograms/kg PAF produces lethal anaphylactic shock. Sensitivity varies with strain and source: Swiss Webster mice show a range of sensitivity and DBA/2 (complement C5-deficient) mice are very resistant. At lethal doses of PAF, animals show labored respiration and general depression; death occurs within 15-45 min. Dexamethasone administered at least 1.5 hr prior consistently protects, whereas the cyclooxygenase inhibitors do not. Antihistamines, adrenergic antagonists, and methysergide have no effect, but cyproheptadine is partially protective at near lethal doses. Calcium entry blockers and calcium chelators, tetracycline and chlortetracycline are partially protective at very high doses consistent with non-specific effects on calcium dependent processes. The arachidonic acid lipoxygenase inhibitors BW755c, phenidone, nordihydroguaiaretic acid and diphenyldisulfide provide nearly complete protection after oral administration of 50-200 mg/kg. Phosphodiesterase inhibitors and dapsone are also effective orally. The leukotriene antagonist FPL55712 administered intraperitoneally (10 mg/kg) 5 min. prior to PAF challenge provides almost complete protection. PAF-induced mortality in the mouse represents a small animal model of systemic anaphylaxis particularly useful for the systemic testing of arachidonic acid lipoxygenase inhibitors and leukotriene antagonists.
D000707:Anaphylaxis; D000818:Animals; D002738:Chloroquine / Q000494:pharmacology; D002751:Chlortetracycline / Q000494:pharmacology; D003907:Dexamethasone / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005260:Female; D007213:Indomethacin / Q000494:pharmacology; D007275:Injections, Intravenous; D008297:Male; D051379:Mice; D008811:Mice, Inbred DBA; D009288:Naproxen / Q000494:pharmacology; D009529:Nicardipine; D009543:Nifedipine / Q000031:analogs & derivatives / Q000494:pharmacology; D010972:Platelet Activating Factor / Q000008:administration & dosage / Q000633:toxicity*; D011720:Pyrazoles / Q000494:pharmacology; D011796:Quinacrine / Q000494:pharmacology; D013752:Tetracycline / Q000494:pharmacology; D014700:Verapamil / Q000494:pharmacology
D010972:Platelet Activating Factor; D011720:Pyrazoles; D009288:Naproxen; D003907:Dexamethasone; D002738:Chloroquine; D014700:Verapamil; D009529:Nicardipine; D013752:Tetracycline; D011796:Quinacrine; C015429:phenidone; D009543:Nifedipine; D002751:Chlortetracycline; D007213:Indomethacin